See more : Azimut Exploration Inc. (AZM.V) Income Statement Analysis – Financial Results
Complete financial analysis of Titan Pharmaceuticals, Inc. (TTNP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Titan Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Star Equity Holdings, Inc. (STRRP) Income Statement Analysis – Financial Results
- PT Bayan Resources Tbk (BYAN.JK) Income Statement Analysis – Financial Results
- Peace Arch Entertainment Group Inc. (PAEGF) Income Statement Analysis – Financial Results
- Dongkuk Structures & Construction Company Limited (100130.KQ) Income Statement Analysis – Financial Results
- Gosuncn Technology Group Co., Ltd. (300098.SZ) Income Statement Analysis – Financial Results
Titan Pharmaceuticals, Inc. (TTNP)
About Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 184.00K | 60.00K | 1.53M | 4.84M | 3.61M | 5.91M | 215.00K | 15.07M | 1.67M | 3.65M | 10.48M | 7.12M | 4.07M | 10.09M | 79.00K | 70.00K | 24.00K | 32.00K | 89.00K | 31.00K | 89.00K | 2.89M | 4.57M | 1.88M | 300.00K | 100.00K | 17.50M | 300.00K | 100.00K |
Cost of Revenue | 112.00K | 196.00K | 199.00K | 472.00K | 1.29M | 538.00K | 9.65M | 6.13M | 4.68M | 4.08M | 8.31M | 10.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -196.00K | -400.00K | -300.00K | -400.00K | -500.00K | -300.00K |
Gross Profit | 72.00K | -136.00K | 1.33M | 4.37M | 2.32M | 5.37M | -9.43M | 8.94M | -3.00M | -429.00K | 2.17M | -3.49M | 4.07M | 10.09M | 79.00K | 70.00K | 24.00K | 32.00K | 89.00K | 31.00K | 89.00K | 2.89M | 4.57M | 2.08M | 700.00K | 400.00K | 17.90M | 800.00K | 400.00K |
Gross Profit Ratio | 39.13% | -226.67% | 86.96% | 90.24% | 64.33% | 90.90% | -4,387.44% | 59.34% | -179.77% | -11.77% | 20.72% | -49.08% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 110.43% | 233.33% | 400.00% | 102.29% | 266.67% | 400.00% |
Research & Development | 1.91M | 4.76M | 5.69M | 5.92M | 7.24M | 7.48M | 9.65M | 6.13M | 4.68M | 4.08M | 8.31M | 10.61M | 11.21M | 12.86M | 2.46M | 16.24M | 12.24M | 11.62M | 17.77M | 20.42M | 22.26M | 29.82M | 23.34M | 16.74M | 9.40M | 7.80M | 18.80M | 5.60M | 0.00 |
General & Administrative | 5.55M | 6.03M | 4.99M | 5.80M | 5.40M | 0.00 | 5.07M | 4.60M | 3.76M | 3.05M | 3.06M | 4.88M | 3.37M | 3.26M | 3.44M | 9.76M | 6.21M | 4.86M | 5.37M | 5.24M | 5.11M | 5.08M | 5.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 6.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 5.55M | 6.03M | 4.99M | 5.80M | 11.93M | 6.87M | 5.07M | 4.60M | 3.76M | 3.05M | 3.06M | 4.88M | 3.37M | 3.26M | 3.44M | 9.76M | 6.21M | 4.86M | 5.37M | 5.24M | 5.11M | 5.08M | 5.38M | 4.07M | 2.80M | 3.70M | 6.50M | 5.30M | 9.50M |
Other Expenses | -183.00K | -497.00K | -84.00K | 1.72M | 17.00K | -6.00K | -55.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 0.00 | 0.00 | 0.00 | 759.00K | 3.90M | 0.00 | 0.00 | 196.00K | 400.00K | 300.00K | 400.00K | 500.00K | 300.00K |
Operating Expenses | 7.28M | 10.30M | 10.68M | 11.72M | 19.17M | 13.64M | 14.72M | 10.72M | 8.43M | 7.12M | 11.37M | 15.49M | 14.57M | 16.12M | 5.89M | 25.99M | 18.46M | 16.48M | 23.14M | 25.65M | 27.37M | 34.90M | 28.72M | 21.01M | 12.60M | 11.80M | 25.70M | 11.40M | 9.80M |
Cost & Expenses | 7.46M | 10.30M | 10.88M | 12.19M | 20.46M | 14.18M | 14.72M | 10.72M | 8.43M | 7.12M | 11.37M | 15.49M | 14.57M | 16.12M | 5.89M | 25.99M | 18.46M | 16.48M | 23.14M | 25.65M | 27.37M | 34.90M | 28.72M | 20.81M | 12.20M | 11.50M | 25.30M | 10.90M | 9.50M |
Interest Income | 5.00K | 53.00K | 1.00K | 769.00K | 967.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 646.00K | 717.00K | 570.00K | 673.00K | 1.28M | 4.22M | 6.76M | 5.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 1.00K | 769.00K | 967.00K | 887.00K | 369.00K | 37.00K | 0.00 | 0.00 | 1.57M | 4.86M | 6.43M | 678.00K | 6.00K | 470.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00M | 1.90M |
Depreciation & Amortization | 112.00K | 196.00K | 221.00K | 292.00K | 244.00K | 380.00K | 417.00K | 377.00K | 358.00K | 353.00K | 107.00K | 17.00K | 32.00K | 85.00K | 169.00K | 210.00K | 288.00K | 389.00K | 405.00K | 466.00K | 439.00K | 1.57M | 647.00K | 196.00K | 400.00K | 300.00K | 400.00K | 500.00K | 300.00K |
EBITDA | -7.17M | -10.04M | -9.13M | -7.06M | -6.28M | -7.88M | -14.09M | 4.72M | -6.40M | -3.12M | -784.00K | -8.35M | -10.51M | -6.07M | -5.65M | -25.22M | -18.15M | -16.06M | -22.65M | -25.54M | -26.84M | -30.43M | -23.50M | -18.74M | -11.50M | -11.20M | -7.40M | -10.00M | -9.10M |
EBITDA Ratio | -3,894.02% | -16,731.67% | -641.81% | -110.42% | -496.70% | -135.65% | -6,839.07% | 26.32% | -112.57% | -115.03% | -123.60% | -117.37% | -300.07% | -57.55% | -7,064.56% | -35,357.14% | -76,187.50% | -50,159.38% | -25,466.29% | -77,738.71% | -25,786.52% | -1,038.52% | -512.38% | -730.21% | -3,800.00% | -12,000.00% | -92.00% | -3,266.67% | -8,700.00% |
Operating Income | -7.28M | -10.24M | -9.35M | -7.35M | -16.84M | -8.26M | -14.50M | 4.34M | -6.76M | -3.48M | -891.00K | -8.37M | -10.51M | -6.03M | -5.82M | -25.92M | -18.43M | -16.45M | -23.05M | -26.38M | -31.17M | -32.00M | -24.15M | -18.93M | -11.90M | -11.40M | -7.80M | -10.60M | -9.40M |
Operating Income Ratio | -3,954.89% | -17,058.33% | -612.98% | -151.94% | -466.46% | -139.81% | -6,745.12% | 28.83% | -404.49% | -95.31% | -8.50% | -117.61% | -258.26% | -59.69% | -7,360.76% | -37,028.57% | -76,804.17% | -51,396.88% | -25,900.00% | -85,096.77% | -35,026.97% | -1,106.60% | -528.22% | -1,007.13% | -3,966.67% | -11,400.00% | -44.57% | -3,533.33% | -9,400.00% |
Total Other Income/Expenses | 1.71M | 29.00K | 578.00K | -56.00K | 386.00K | -759.00K | 195.00K | 792.00K | -4.52M | 1.07M | 10.60M | -6.81M | -4.70M | -809.00K | -71.00K | 490.00K | 786.00K | 710.00K | 589.00K | 376.00K | 1.29M | 3.82M | 6.69M | -5.01M | -100.00K | 999.00K | 8.70M | -400.00K | -400.00K |
Income Before Tax | -5.57M | -10.21M | -8.78M | -7.41M | -16.46M | -9.02M | -14.31M | 5.14M | -11.28M | -2.40M | 9.71M | -15.18M | -15.20M | -6.83M | -5.88M | -25.43M | -17.65M | -15.74M | -22.46M | -26.00M | -29.89M | -28.18M | -17.46M | -23.94M | -12.00M | -10.50M | 900.00K | -10.90M | -9.80M |
Income Before Tax Ratio | -3,026.63% | -17,010.00% | -575.10% | -153.10% | -455.77% | -152.65% | -6,654.42% | 34.09% | -674.99% | -65.91% | 92.65% | -213.29% | -373.72% | -67.71% | -7,443.04% | -36,328.57% | -73,529.17% | -49,178.13% | -25,238.20% | -83,883.87% | -33,583.15% | -974.48% | -381.98% | -1,273.62% | -4,000.00% | -10,500.00% | 5.14% | -3,633.33% | -9,800.00% |
Income Tax Expense | 0.00 | -29.00K | -662.00K | 13.32M | -369.00K | -1.65M | -250.00K | -792.00K | 4.52M | -1.07M | -10.60M | 4.86M | 4.70M | 809.00K | 71.00K | 960.00K | -786.00K | -710.00K | -589.00K | 383.00K | 2.61M | -3.82M | -6.69M | -146.00K | -600.00K | -800.00K | -8.40M | 2.30M | 2.30M |
Net Income | -5.57M | -10.18M | -8.11M | -20.73M | -16.09M | -9.02M | -14.31M | 5.14M | -11.28M | -2.40M | 9.71M | -15.18M | -15.20M | -6.83M | -5.89M | -25.43M | -17.65M | -15.74M | -22.46M | -26.00M | -29.89M | -28.18M | -17.46M | -18.79M | -11.30M | -10.60M | 600.00K | -12.90M | -11.70M |
Net Income Ratio | -3,026.63% | -16,961.67% | -531.72% | -428.44% | -445.56% | -152.65% | -6,654.42% | 34.09% | -674.99% | -65.91% | 92.65% | -213.29% | -373.72% | -67.71% | -7,450.63% | -36,328.57% | -73,529.17% | -49,178.13% | -25,238.20% | -83,883.87% | -33,583.15% | -974.48% | -381.98% | -999.36% | -3,766.67% | -10,600.00% | 3.43% | -4,300.00% | -11,700.00% |
EPS | -7.41 | -15.15 | -16.68 | -109.88 | -12.60K | -47.59 | -121.48 | 44.71 | -101.24 | -25.36 | 117.00 | -227.70 | -253.71 | -114.20 | -99.66 | -14.37 | -406.32 | -411.06 | -681.41 | -820.39 | -1.06K | -1.01K | -626.56 | -726.84 | -694.36 | -800.60 | 39.60 | -1.03K | -1.53K |
EPS Diluted | -7.41 | -15.15 | -16.68 | -109.88 | -12.60K | -47.59 | -121.34 | 36.01 | -101.24 | -25.35 | 95.40 | -225.96 | -249.23 | -114.20 | -99.66 | -14.37 | -406.32 | -411.06 | -681.41 | -820.39 | -1.06K | -1.01K | -626.56 | -726.84 | -694.36 | -800.60 | 39.60 | -1.03K | -1.53K |
Weighted Avg Shares Out | 752.00K | 671.70K | 486.50K | 188.65K | 1.28K | 189.60K | 117.78K | 115.21K | 111.40K | 94.76K | 82.93K | 66.67K | 59.92K | 59.85K | 59.06K | 1.77M | 43.43K | 38.28K | 32.96K | 31.70K | 28.19K | 27.92K | 27.87K | 25.85K | 16.27K | 13.24K | 15.15K | 12.52K | 7.64K |
Weighted Avg Shares Out (Dil) | 752.00K | 671.70K | 486.50K | 188.65K | 1.28K | 189.60K | 117.91K | 119.21K | 111.40K | 94.78K | 83.49K | 67.18K | 61.00K | 59.85K | 59.06K | 1.77M | 43.43K | 38.28K | 32.96K | 31.70K | 28.19K | 27.92K | 27.87K | 25.85K | 16.27K | 13.24K | 15.15K | 12.52K | 7.64K |
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. – TTNP
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. - TTNP
Shareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders
TTNP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Titan Pharmaceuticals, Inc. Is Fair to Shareholders
Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio
Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors
Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock
Source: https://incomestatements.info
Category: Stock Reports